3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasm Metastasis
4
Lung Neoplasms
4
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Camurati-Engelmann Syndrome
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
bintrafusp alfa protein, human
×
Clear all
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts